simvastatin / Generic mfg. - LARVOL DELTA

Risk of new-onset diabetes across individual statins in secondary prevention: results from the Korean national health insurance service cohort. (PubMed, Front Cardiovasc Med) - "In the moderate-intensity group, rosuvastatin (adjusted HR 1.07, 95% CI 1.01-1.14), pravastatin (HR 1.19, 95% CI 1.02-1.38), and simvastatin (HR 1.15, 95% CI 1.06-1.20) were associated with higher NODM risk compared with atorvastatin, while fluvastatin and pitavastatin showed no significant differences. In this nationwide secondary prevention cohort, the risk of NODM differed across individual statins despite comparable cardiovascular outcomes. These findings suggest that the diabetogenic effect of statins may be agent-specific rather than a uniform class effect, highlighting the importance of individualized statin selection balancing metabolic and cardiovascular benefits."

Journal • Reimbursement • US reimbursement • Atherosclerosis • Cardiovascular • CNS Disorders • Diabetes • Metabolic Disorders

Ameliorative effect of Rhus verniciflua Stokes on high-fat diet-induced obesity and advanced analysis with machine learning and deep learning-based network pharmacology. (PubMed, Life Sci) - "These results demonstrate that RVS ameliorates HFD-induced obesity and MASLD through redox-metabolic pathway modulation, with systemic efficacy likely arising from the synergistic contributions of parent compounds, their Phase II conjugates, and gut microbial metabolites."

Journal • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • FASN

SIMFIB: Efficacy of Simvastatin in Alcoholic Liver Fibrosis (clinicaltrials.gov) - P2/3 | N=90 | Recruiting | Sponsor: Anna Cruceta | Not yet recruiting ➔ Recruiting

Enrollment open • Fibrosis • Hepatology • Immunology • Liver Cirrhosis

Efficacy of topical application of simvastatin gel combined with a collagen sponge carrier in preserving alveolar ridge dimensions: a triple-blind randomized clinical trial. (PubMed, Clin Oral Investig) - No abstract available

Clinical • Journal • Osteoporosis

Muscle atrophy associated with glucagon-like Peptide-1 receptor agonists: A population-based observational study. (PubMed, Clin Nutr) - "To contextualize associations, disproportionality estimates were calculated using niacin, simvastatin, and the complete FAERS database (all other drugs) as comparators...In contrast, exenatide (ROR = 0.26, 95 % CI = 0.12-0.55) and liraglutide (ROR = 0.27, 95 % CI = 0.09-0.83) were associated with significantly lower reporting odds...ConclusionsCertain GLP-1 receptor agonists demonstrate a pharmacovigilance signal of disproportionate reporting of muscle atrophy. These findings should be interpreted as signal detection rather than evidence of causality and highlight the need for future studies incorporating objective measures of muscle mass and function.."

Journal • Observational data • Muscular Atrophy

Economic Evaluation of Pre-emptive Pharmacogenetic Panel Testing versus No Genetic Testing in a Multi-ethnic Asian Population. (PubMed, Pharmacoeconomics) - "Pre-emptive PGx panel testing is economically viable when panel design, variant prevalence, drug costs, and local prescribing patterns are carefully considered. As more data become available, the model can be tailored to evaluate additional drug-gene pairs and their downstream consequences."

Biomarker • HEOR • Journal • CYP2C19 • DPYD • HLA-B

STATIN USE, LDL-C LEVELS, AND COGNITIVE DECLINE IN ALZHEIMER'S DISEASE: A SWEDISH REGISTRY-BASED COHORT STUDY (ADPD 2026) - "Statin use (simvastatin, atorvastatin, or rosuvastatin) was modeled as a time-varying exposure based on prescription data. Statin use, particularly simvastatin, was associated with slower cognitive decline among AD patients, especially those with higher LDL-C levels. These findings suggest that both statin therapy and lipid status may jointly influence cognitive trajectories in AD."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Dyslipidemia

LIPOPHILIC STATINS AND RISK OF PARKINSON'S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS (ADPD 2026) - "While lipophilic statins overall did not significantly affect PD risk; certain lipophilic statins like simvastatin, lovastatin and atorvastatin, showed a significant protective effect. Further research is needed to confirm the neuroprotective potential and clinical applications of statins."

Retrospective data • Review • CNS Disorders • Dyslipidemia • Movement Disorders • Parkinson's Disease

NEURON-DERIVED ALPHA-SYNUCLEIN TRIGGERS ABERRANT CHOLESTEROL ACCUMULATION IN GLIAL CELLS (ADPD 2026) - "We showed that simvastatin reduces α-syn accumulation and transmission, alleviating pathology... Our findings demonstrate that astrocytic cholesterol regulation and enhanced vesicle trafficking are central to α-syn propagation and neuronal vulnerability in PD. These results highlight astrocytic cholesterol metabolism as a novel mechanistic axis and propose it as a promising therapeutic target for disease modification."

GFAP

Bisphosphonate and statin: adverse effects of co-medication on wound healing in in vitro models of periodontal tissues. (PubMed, Acta Odontol Scand) - "High concentrations of simvastatin, alone or combined with alendronate, may have a negative impact on angiogenetic markers and cell migration/proliferation, affecting wound healing and growth."

Adverse events • Journal • Preclinical • CASP3 • CXCL8 • IL6

Combination therapies for vitiligo: a systematic review and network meta-analysis (AAD 2026) - "Simvastatin improved continuous outcomes (SMD 0.58; 0.02-1.15), but lost significance under a conservative correlation assumption (r=0.3). Gliadin-protected super oxide dismutase, methotrexate, silymarin, apremilast, pseudocatalase, alpha-lipoic acid, antioxidant cocktail, tacrolimus, pimecrolimus, and mometasone were not significant. These findings highlight baricitinib and piperine as promising candidates for future guideline integration and underscore the need for larger, high-quality RCTs to confirm their role in optimizing vitiligo treatment."

Combination therapy • Retrospective data • Review • Dermatology • Immunology • Vitiligo • CAT

Eosinophilic-Rich Linear Immunoglobulin A Bullous Dermatosis (AAD 2026) - "The drug-induced variant is most commonly linked to vancomycin, though other implicated agents include trimethoprim-sulfamethoxazole, amoxicillin, nonsteroidal anti-inflammatory drugs, simvastatin, cyclosporine, furosemide, lithium, and various additional medications...Treatments—including metronidazole gel, prednisone, triamcinolone, mupirocin, and doxycycline—provided minimal relief...Eosinophil-rich LABD has been infrequently reported in both adult and pediatric patients. Known associations include COVID-19 vaccination, parvovirus B19 infection, hematologic malignancies, and certain medications."

Alopecia • Cough • Dermatology • Hematological Malignancies • Infectious Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Novel Coronavirus Disease • Orthopedics • Pruritus • Respiratory Diseases

Efficacy of Statins in Adjunctive Treatment of Vitiligo: A Systematic Review and Meta-Analysis (AAD 2026) - "The trials assessed simvastatin or atorvastatin, administered orally in 75% and topically in 25%. Statins should not replace standard therapies but may serve as adjuncts pending further validation. Future trials must improve methodological quality and clarify patient subgroups most likely to benefit."

Retrospective data • Review • Dermatology • Immunology • Vitiligo

Assessment of the dentine microhardness following the application of different intracanal medicaments. An in-vitro study. (PubMed, BDJ Open) - "Bio-C Temp, and m-TAP nanofibers demonstrated superior ability to preserve dentine microhardness, suggesting their promising potential advantage over conventional medicaments for strengthening root dentine."

Journal • Preclinical

Comparing the intrahepatic effects of carvedilol and simvastatin in experimental liver cirrhosis (EASL 2026) - No abstract available

Fibrosis • Gastroenterology • Hepatology • Immunology • Liver Cirrhosis

Simvastatin attenuates post-hepatectomy hemodynamic liver injury in fibrotic livers through KLF2-eNOS signaling (EASL 2026) - No abstract available

Fibrosis • Hepatology • Liver Failure • NOS3

Imanixil-mediated disruption of lipid trafficking impairs hepatic hemoglobin clearance in Sickle cell Disease (THSNA 2026) - "Moreover, using a small molecule inhibitor screen we further demonstrated that Hbs internalizes to LSECS through a slow, pH-dependent, lipid-dependent fluid-phase endocytic mechanism, where lipid supplementation significantly enhances Hb uptake and lipid depletion through simvastatin, nystatin, or the cholesterol-lowering agent Imanixil significantly impairs endothelial Hb internalization. These findings demonstrate that both LSECs and Kupffer cells depend on lipid-mediated endocytic pathways for efficient Hb clearance, establishing lipid availability as a major regulator of hepatic Hb regulation. Also, this study identifies lipid trafficking disruption as a mechanistic barrier to Hb detoxification and provides a foundation for future studies aimed at defining molecular lipid–endocytic pathway regulation and developing therapeutic strategies to mitigate hemolysis-associated liver injury in SCD. No part of this publication may be reproduced, distributed, or transmitted..."

Genetic Disorders • Hematological Disorders • Hepatology • Inflammation • Liver Failure • Sickle Cell Disease

ATORVASTATIN METABOLITES WITH ANTIOXIDANT ACTIONS LIMIT RAPID OXIDATION OF LIPOPROTEIN(A)-ENRICHED PLASMA MORE EFFECTIVELY THAN OTHER STATINS (ACC 2026) - "We compared the metabolites' effects to other active statins - pitavastatin, rosuvastatin, pravastatin, and simvastatin - on oxidation in plasma samples enriched with Lp(a) and other atherogenic lipoproteins, including small dense LDL (sdLDL). Active metabolites of atorvastatin inhibited oxidation of Lp(a), sdLDL, and LDL enriched plasma compared to other widely used statins as well as in cholesterol-enriched lipid membranes, likely due to free radical scavenging. The potent antioxidant actions of atorvastatin active metabolites may reduce atherogenicity of Lp(a) in patients independent of the production of this atherogenic particle."

Atherosclerosis • Cardiovascular • APOB

Topical Statins in Dermatology: A Scoping Review of Promising Therapy for Select Skin Disorders (AAD 2026) - " A comprehensive literature review included studies on topical atorvastatin, simvastatin, and lovastatin for porokeratosis, seborrheic dermatitis, chronic hand eczema, psoriasis, acne vulgaris, and vitiligo... Topical statins showed promise for porokeratosis, seborrheic dermatitis, and chronic hand eczema, likely via anti-inflammatory mechanisms. Evidence does not support use in psoriasis, acne, or vitiligo, highlighting potential risks in psoriasis. Limitations include heterogeneous study designs, small sample sizes, and limited long-term follow-up."

Review • Acne Vulgaris • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis • Seborrheic Dermatitis • Vitiligo

Co-Inhibition of Kv1.3 Channel Activity by Selected Chalcones and Statins in a Model of Cancer Cell Line Jurkat T. (PubMed, Molecules) - "The inhibitory effect of IBC was significantly enhanced upon co-application with simvastatin (SIM) and mevastatin (MEV)...The channel inhibition may be related to the anti-proliferative and pro-apoptotic activities of these compounds in Kv1.3-expressing cancer cells. Altogether, our results indicate that both prenylated and non-prenylated chalcones, particularly in combination with statins, may represent biologically active scaffolds, warranting further optimization and preclinical evaluation."

Journal • Preclinical • Oncology

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. (PubMed, J Am Coll Cardiol) - "The "2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia" retires and replaces the "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol." A comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a)."

Clinical guideline • Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Hypertriglyceridemia • Metabolic Disorders • PCNA

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. (PubMed, Circulation) - "The "2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia" retires and replaces the "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol." A comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a)."

Clinical guideline • Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Hypertriglyceridemia • Metabolic Disorders • PCNA

Assembly Module-Empowering Lipid-Prodrug Nanoamplifier for Enhancing Ferroptosis-Driven Cancer Treatment. (PubMed, Nano Lett) - "To address this limitation, we developed a lipid-prodrug nanoamplifier (SIM-SS-LA NAs), composed of disulfide-linked linoleic alcohol and simvastatin (SIM) to enhance ferroptosis...Notably, the released LA acts as an exogenous substrate, substantially increasing lipid peroxide accumulation and synergizing with SIM-mediated GPX4 inhibition to amplify ferroptosis. As expected, the lipid-prodrug nanoamplifier showed potent ferroptosis-driven antitumor activity in a 4T1 breast tumor-bearing mouse model, offering an efficient nanotherapeutic strategy for ferroptosis-based cancer therapy."

Journal • Breast Cancer • Oncology • Solid Tumor • GPX4

An Engineered SIM@ZIF-8 Hydrogel Synergistically Enhances Vascularized Bone Regeneration in an Osteoporotic Environment. (PubMed, ACS Appl Mater Interfaces) - "This system innovatively integrates simvastatin (SIM) loaded zeolite imidazolate skeleton-8 (ZIF-8) nanoparticles into a methacrylated chitosan-gelatin matrix, endowing the material with controllable mechanical properties and a long-lasting local bioactive factor reservoir...This system thus effectively coordinates the "osteogenic-angiogenic coupling" that is often disrupted in the osteoporotic environment and significantly accelerates angiogenic bone regeneration under osteoporotic conditions in both in vitro and in vivo experiments. This study proposes an efficient biomaterial strategy that achieves a breakthrough in the traditional single-factor delivery model by collaboratively targeting multiple pathological dimensions of osteoporotic bone defects."

Journal • Osteoporosis • Rheumatology

Dingxin Recipe III resolves atherosclerotic inflammation via revitalizing Regulatory T cell lineage fidelity associated with fatty acid oxidation metabolic reprogramming. (PubMed, Phytomedicine) - "DXR III ameliorates atherosclerosis, a process closely associated with the modulation of the FAO metabolic checkpoint to correct the immune imbalance driving plaque progression. By rescuing the Treg differentiation, functional integrity, and phenotypic fidelity while avoiding the immunological trade-offs associated with Th1/Th17, DXR III represents a promising candidate for comprehensive cardiovascular protection."

Journal • Preclinical • Atherosclerosis • Cardiovascular • Diabetes • Inflammation • APOE